Single answer

Is Nuvalent Inc (NUVL) a buy or sell?

4starter turns market data into one clear verdict you can act on.

Sell
$107.17
+2.22 (+2.12%)
Quote updated: 2026-02-03 21:00 UTC
Trend today
+2.12%
Up today
Volume vs avg
44.13%
0.56x under average
Target gap
24.19%
above current price
Signal updated
2026-02-03 20:56 UTC
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
Add to watchlist

Create a free account to save tickers and track your signals.

Log in to turn on watchlist alerts.

Decision snapshot

Everything you need to act fast, in one glance.

4starter signal
Sell
20%
Score
Confidence score
Higher scores mean stronger signal alignment.

Powered by momentum, volatility, and trend inputs.

Analyst target gap
24.19%
$25.92 above current price

Consensus target $133.09.

Volume vs average
44.13%
under average

337,908 vs 604,838 average (0.56x normal).

What is the conclusion?

Right now our advanced algorithms say:

NO

$1 invested is now $1.24 or 24.00%

(In 13 weeks 1 day 20 hours 30 minutes and 39 seconds .)

Do analysts agree?

We compare consensus targets with today's price.

NO

Consensus target for Nuvalent Inc is $133.09, which is $25.92 (24.19%) above the current price today's price.

Low target: $105.00 | High target: $155.00

Latest analyst updates

Recent rating and price target changes for this stock.

2025-11-24 | Truist Financial | Target 140.00
2025-11-17 | Leerink Partners | Target 149.00
2025-11-17 | H.C. Wainwright | Target 155.00
2025-11-12 | Canaccord Genuity | Target 126.00

Company snapshot

A quick overview of the business and its public profile.

Nuvalent Inc a clinical stage biopharmaceutical company develops therapies for patients with cancer Its lead product candidates are NVL520 a brainpenetrant ROS1selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drugresistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors which is under Phase I development and NVL655 a brainpenetrant ALKselective inhibitor to address the clinical challenges of emergent treatment resistance central nervous systemrelated adverse events and brain metastases that might limit the use of first second and thirdgeneration ALK inhibitors that is under Phase III clinical trial The company was incorporated in 2017 and is headquartered in Cambridge Massachusetts

Website: https://www.nuvalent.com

Rates and inflation backdrop

US inflation for December 2025 was 0.31%. Over the last 12 months, inflation is 3.03%. The 10-year yield is 4.29 and is up 0.240 over the last 30 days.

Inflation sensitivity

Debt ratio: 0.00. Cash flow to debt ratio: 0.00. Net profit margin: 0.00%. Inflation risk score: medium (0.60/1).

Dividend history check

We cannot find any recorded dividends paid in our systems.

Trading liquidity

Yes, the average daily trading liquidity for Nuvalent Inc is $56M. You should therefore be able to get in and out of your positions relatively fast.

10-year return check

We cannot find data for Nuvalent Inc 10 years ago, but if you had invested on 2021-07-29 when the price was $18.75, you would have made a profit of $88.42 per share or 471.57%.

Why this answer

We combine price momentum, volatility, and trend signals to simplify the decision to one word.

1

Signal engine scans price, trend, and momentum indicators.

2

Targets and sentiment are checked against the live quote.

3

We keep the output simple: buy, sell, or hold.

Analyst consensus

How Wall Street targets compare to today's price.

$133.09
$25.92 (24.19%) above the current price
Range: $105.00 - $155.00

FAQ

Today's 4starter signal is Sell. That means the current data favors caution over upside.

Quotes and targets refresh throughout the trading day, with the latest timestamp shown on the page.

It blends momentum, trend, and volatility indicators into a single decision-oriented verdict.